![](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/thumbnail/S0001731023008700:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9/t1/zx4Q/XH5Tma1a/6fSs=)
Área salud
[Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?
Systemic treatment with immunotherapy or targeted therapy can significantly improve survival in patients with advanced (metastatic or high-risk) melanoma. Fifty percent of patients with melanoma have a BRAF mutation. Decisions on optimal sequencing of systemic […]